Our core competence is NanoGAS® technology, which enables the long-term stabilization of nano-scale bubbles over several years. In the healthcare sector, we have leveraged this technology to develop a pioneering Fecal Microbiota Transplantation (FMT) technique. Its efficacy and safety have been validated through "Specific Clinical Research" regarding its impact on Autism Spectrum Disorder (ASD). Furthermore, we have established robust clinical evidence, including a 50% reduction in healing time for pressure ulcers and a 50% decrease in the volume of laxatives required for endoscopic procedures. Beyond medicine, NanoGAS® provides superior oxidation inhibition (anti-corrosion) and antibacterial effects. With a proven track record in maintaining the hygiene of humidifiers, our technology is available for licensing and joint development to dramatically enhance the value of products across diverse fields—from healthcare to industrial and HVAC infrastructure.
シンバイオシス株式会社（本社：大阪府大阪市、代表取締役：田中三紀子）は、自閉スペクトラム症（ASD）児を対象とした、新たに開発した次世代FMT（NanoGAS(R)-FMT）法の有効性と安全性に関する特定臨床研究に関...
シンバイオシス株式会社（本社：大阪市、代表取締役：田中 三紀子）は、10年以上の長期安定性を誇る独自技術「水素NanoGAS(R)水」の医療領域における用途特許を出願いたしました。本件は、当社の基盤技術（特許第...
We develop and sell therapeutic drugs and skin care cosmetics, focusing on drug transdermal absorption technology that can absorb both water-soluble and hydrophobic compounds of large molecular weight. In particular, in joint research with Kobe University, we found that carbon dioxide transdermal absorption has an increase and activation effect on mitochondria, and it has been revealed that it can safely increase muscle strength, promote healing of wounds/fractures, and inhibit scarring, partial weight loss by promoting fat metabolism, and induce apoptosis in cancer cells. Some products are on the market not only in Japan but also in other countries.
【Neoself Platform for Clinical Diagnostics and Drug Development】 AOI Bio leverages a newly discovered mechanism, coined Neoself, underlying autoimmune diseases to provide diagnostic services and to develop novel therapeutics. AOI Bio. currently offers clinical testing for the B2GPI Neoself Antibody in patients with unexplained recurrent pregnancy or implantation failures. 【Bioinformatics Analysis Platform for Drug Discovery】 AOI Bio employs advanced computational methods to identify novel biomarkers and drug candidates. By utilizing industry-leading solutions, such as quantum-optimized allosteric pocket identification, AOI Bio. drives its groundbreaking drug development efforts forward.
A biotech startup developing T-cell and NK-cell therapies derived from low-immunogenicity iPS cells. It aims to provide new treatments for solid tumors and autoimmune diseases, contributing to the treatment of previously difficult-to-treat intractable diseases.
We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.